However, major generic drug manufacturers are planning to launch generic semaglutide in Canada as early as next year
This creates a dual burden for CDMOs: scaling fast enough to meet market need, while simultaneously meeting higher expectations from authorities including the FDA, EMA, and others
While the branded versions are FDA-approved for specific uses, compounded versions are prepared based on individual prescriptions and are often used during periods of medication shortages
Success will depend on disciplined translational design, early integration of manufacturing and regulatory planning, and a realistic assessment of the competitive landscape
It requires expertise in multiple areas
ADVERSE REACTIONS: Intramuscular injection can cause skin rashes, itching, diarrhea, and allergic asthma